Studies on HBcAg-rBlo t 5-21 Fusion Protein Vaccine That Alleviates Blomia tropicalis Airway Inflammation.
Studies on HBcAg-rBlo t 5-21 Fusion Protein Vaccine That Alleviates Blomia tropicalis Airway Inflammation.
复制标题
HBcAg-rBlo t 5-21 融合蛋白疫苗减轻热带布洛米亚气道炎症的研究
DOI：
10.2147/jir.s380526
复制
发表时间：
2022
影响因子：
4.5
通讯作者：
Wang, Dayong
中科院分区：
文献类型：
--
作者：
Pei, Yechun;Xiao, Zhengpan;Wei, Shuangshuang;Peng, Meiqi;Luo, Chenghui;Wang, Dayong
背景 在热带和亚热带地区，来自尘螨物种热带布洛米亚的过敏原是过敏性鼻炎和哮喘的常见原因。热带水菌有两种主要过敏原：Blo t 5 和 Blo t 21。目的是产生一种含有 HBcAg、Blo t 5 和 Blo t 21 的嵌合病毒样颗粒，可以治疗热带水菌引起的过敏。方法 为了在小鼠中产生过敏性哮喘，本研究采用原核表达和纯化热带菌过敏原 rBlo t 5、rBlo t 21 和重组融合过敏原 rBlo t 5-21。我们创建了乙型肝炎核心抗原（HBcAg）和rBlo t 5-21融合原核表达质粒。 HBcAg-rBlo t 5-21 表达后进行纯化，并通过透射电子显微镜 (TEM) 进行测试。此外，蛋白质 HBcAg-rBlo t 5-21 被用作蛋白质疫苗。结果 在过敏诱导的小鼠模型实验中，融合过敏原 rBlo t 5-21 比单独过敏原 rBlo t 5 和 rBlo t 21 诱导过敏更有效。我们发现，用重组融合蛋白疫苗 HBcAg-rBlo t 5-21 接种过敏小鼠可以减轻 rBlo t 5-21 过敏原引起的过敏症状。与 PBS 组相比，接种 HBcAg-rBlo t 5-21 疫苗可降低总血清 IgE 水平，抑制过敏反应，并减少炎症细胞浸润至肺组织。结论 HBcAg-rBlo t 5-21 是一种同时含有乙型肝炎核心抗原和热带水球菌融合过敏原 rBlo t 5-21 的蛋白疫苗，可能是预防热带水球菌引起的过敏性疾病的合适疫苗。
Background In tropical and subtropical areas, allergens from the dust mite species Blomia tropicalis are common causes of allergic rhinitis and asthma. Blomia tropicalis has two main allergens: Blo t 5 and Blo t 21. Aim To generate a chimeric virus-like particle containing HBcAg, Blo t 5 and Blo t 21 that can treat allergies caused by Blomia tropicalis. Methods To produce allergic asthma in mice, prokaryotic expression and purification of Blomia tropicalis allergens rBlo t 5, rBlo t 21, and recombinant fusion allergen rBlo t 5–21 were utilized in the study. We created a hepatitis B core antigen (HBcAg) and rBlo t 5–21 fusion prokaryotic expression plasmid. HBcAg-rBlo t 5–21 was purified after expression and tested by transmission electron microscopy (TEM). Furthermore, the protein HBcAg-rBlo t 5–21 was employed as a protein vaccination. Results In allergy-induced mouse model experiments, the fusion allergen rBlo t 5–21 was more effective than the individual allergens rBlo t 5 and rBlo t 21 at inducing allergy. We found that vaccinating allergic mice with the recombinant fusion protein vaccine HBcAg-rBlo t 5–21 alleviated allergy symptoms elicited by the rBlo t 5–21 allergen. Vaccination with HBcAg-rBlo t 5–21 resulted in a decrease in total serum IgE levels, suppression of anaphylaxis, and reduction of inflammatory cell infiltration into lung tissue as compared to the PBS group. Conclusion HBcAg-rBlo t 5–21, a protein vaccine containing both the hepatitis B core antigen and the Blomia tropicalis fusion allergen rBlo t 5–21, could be a suitable vaccination for preventing allergy disorders caused by Blomia tropicalis.
影响因子：
--
作者：
Pytelková J;Lepšík M;Sanda M;Talacko P;Marešová L;Mareš M
通讯作者：
Mareš M